care daybook✳

A considered comparison

Mochi alternatives: a more focused shortlist

Compare simpler menus, branded pathways and payment commitments with the exact product in view.

Mochi’s broad menu can be a starting point for care, but some readers want a narrower offering or a different payment arrangement. The relevant alternative depends on which treatment your clinician is considering and which part of the service you want to change.

ServiceProduct distinctionPublished cost contextRead the details
RoApproved options$149/month care membership; medication extraRead review
AmbleCompounded optionsIndividual plan quoteRead review
CoreAge RxCompounded optionsSemaglutide advertised from $79/monthRead review
bmiMDCompounded options$159 one-month semaglutide option; $1,428 annual packageRead review

For a branded pathway with insurance help

Ro is worth examining when the administrative work around an approved branded product is central to your decision. Its care membership has a separate price and the pharmacy bill comes on top. Mochi’s $79 advertised membership alone cannot establish a fair savings comparison: medication, diagnostic costs and the details of the actual clinical plan still matter.

For a simpler compounded-care menu

Amble and CoreAge Rx advertise no separate membership fee. Amble describes compounded injectable GLP-1 care; the CoreAge evidence used here covers compounded semaglutide. This narrows the service comparison but does not settle clinical suitability or legal availability. Compounded drugs are not FDA-approved. Compare the actual prescribed preparation, pharmacy and full supply price.

For a clearly stated package choice

bmiMD lists a one-month compounded semaglutide offer at $159 and a $1,428 annual package. The annual equivalent is lower, but the amount committed is larger. The decision is therefore as much about unused funds and exit terms as about arithmetic. A refund for initial ineligibility does not establish a general refund right after care starts.

Do not trade a known problem for an unknown bill

CoreAge’s $79 and $99 public starting figures remain unresolved, and Amble’s sitewide minimum does not establish a GLP-1 total. Neither can responsibly be called cheaper than Mochi on this evidence. Request two complete written quotes for the same treatment context and compare support, renewal and cancellation alongside the charge.

How we compare

Care Daybook interprets public service information. We have not enrolled as patients or measured clinical quality. Treatment, availability and price depend on individual circumstances. Unknown totals stay unknown.

Our editorial approach · Commercial disclosure

Sources & offer details

Ro official treatment informationFDA Foundayo approvalAmble official treatment informationAmble program overviewFDA: concerns with unapproved GLP-1 drugsCoreAge Rx official treatment informationCoreAge program overviewbmiMD official offering

Confirm current written terms directly. Compounded drugs are not FDA-approved.

Your choice of next step

Continue to the provider

You can continue to the provider you selected, or consider the optional commercial link below.

Continue to the provider

Optional affiliate alternative

CoreAge Rx

Compare CoreAge Rx’s compounded semaglutide plans and current terms. Compounded drugs are not FDA-approved and are not interchangeable with approved medicines.

Explore CoreAge RxRead our reviewWe may earn a commission through the CoreAge Rx link. Continuing to your original provider is always available above.